

For Immediate Release



Press Release

FDA Permits iCAD to Package Second Look Digital with Siemens' Full-Field Digital System

– Joint Solution Offers Effective CAD Choice for the Early Detection of Cancer –

NASHUA, New Hampshire – June 13, 2005 – iCAD®, Inc. (Nasdaq: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions for the early identification of cancer, today announced that the United States Food and Drug Administration (FDA) has permitted iCAD to package its Second Look® Digital offering with Siemens Medical Solutions MAMMOMAT® Novation^{DR} Full-Field Digital System.

The joint solution combines hardware from Siemens with iCAD's leading digital technology and patented algorithms to help doctors and radiologists better detect cancer during a full-field digital mammography exam. With multiple operating points and viewing flexibility, the digital CAD solution automatically identifies and marks regions commonly associated with cancer and views the marks on Siemens' MammoReport^{Plus} softcopy reporting workstation.

"We are committed to helping women worldwide win the fight against breast cancer," said Holger Schmidt, head of the Special Systems Division at Siemens Medical Solutions. "Combining our efforts and mammography solution with an innovative partner like iCAD helps us further that goal."

The MAMMOMAT Novation^{DR} from Siemens utilizes innovative full-field detector technology based on amorphous Selenium (aSe) detector technology. According to Siemens, this technology enables a direct conversion of X-ray to digital information and has the potential to provide higher spatial resolution and greater clinical detail.

"The joint iCAD and Siemens solution gives healthcare professionals assistance in providing patients with accurate and timely mammography results," said W. Scott Parr, President and CEO for iCAD, Inc. "We now have the opportunity to make earlier detection of breast cancer increasingly accessible to women at risk, worldwide."

About Siemens Medical Solutions

Siemens Medical Solutions of Siemens AG (NYSE: SI) with headquarters in Malvern, Pennsylvania and Erlangen, Germany, is one of the largest suppliers to the healthcare industry in the world. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Employing approximately 31,000 people worldwide and operating in more than 120 countries, Siemens Medical Solutions reported sales of 7.07 billion EUR, orders of 8.12 billion EUR and group profit of 1.05 billion EUR for fiscal 2004. More information can be obtained by visiting www.usa.siemens.com/medical-pressroom.

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to identify cancer and other life-threatening conditions earlier by making medical services more effective, more accessible and more affordable for patients worldwide. Recipient of Frost & Sullivan's Growth Strategy Leadership award and repeatedly recognized as offering "The Winning Combination" of Price and Performance by MD Buyline, iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. As the most frequently selected CAD solution for film-based and digital breast screening, iCAD is entrusted with the task of early cancer detection by almost one thousand women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit www.icadmed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company's other filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.

iCAD and Second Look are registered trademarks of iCAD, Inc.

**For iCAD investor relations, contact Kevin McGrath of Cameron Associates
at +1 212 245 4577 or via email at kevin@cameronassoc.com.**

**For all other inquires, contact Monica Pandolfi of SHIFT Communications
at +1 617 681 1235 or via email at mpandolfi@shiftcomm.com.**

###